A reverse genetics system of African horse sickness virus reveals existence of primary replication  by Matsuo, Eiko et al.
FEBS Letters 584 (2010) 3386–3391journal homepage: www.FEBSLetters .orgA reverse genetics system of African horse sickness virus reveals existence
of primary replication
Eiko Matsuo, Cristina C.P. Celma, Polly Roy *
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
a r t i c l e i n f o a b s t r a c tArticle history:
Received 12 May 2010
Revised 14 June 2010
Accepted 18 June 2010
Available online 26 June 2010






T7 transcript0014-5793/$36.00  2010 Federation of European Bio
doi:10.1016/j.febslet.2010.06.030
* Corresponding author. Fax: +44 0 2079272839.
E-mail address: polly.roy@lshtm.ac.uk (P. Roy).African horse sickness virus (AHSV), a member of the orbivirus genus of the family Reoviridae, is an
insect-vectored pathogen of horses of concern to the equine industry. Studies on AHSV replication
and pathogenesis have been hampered by the lack of reverse genetics allowing targeted mutation of
viral genomes. We demonstrate that AHSV single-stranded RNA synthesized in vitro (core tran-
scripts) is infectious and that there are distinct primary and secondary stages of the replication
cycle. Transfection with a mixture of core transcripts from two different serotypes or a mixture
of core transcripts and a T7 derived transcript resulted in the recovery of reassortant viruses. Recov-
ery of infectious ASHV from nucleic acid will beneﬁt investigation of the virus and the generation of
attenuated vaccines.
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African horse sickness virus (AHSV) is the causative agent of Afri-
canhorse sickness (AHS), anOfﬁce International des Epizooties (OIE)
listed disease. AHS has four clinicopathological forms, ranging from
amild fever form to an acute formwith amortality rate of up to 95%
in naïve horses [1]. The high mortality rate results in considerable
economic loss to the equestrian industry. The disease is endemic
to sub-Saharan Africa [1] and is transmitted by midges (Culicoides
spp.) [2], which are the determinant of its geographic range. The
spread of the insect vectors, caused by various factors including cli-
mate change,makes the international expansion of AHSV a very real
possibility [3,4]. Indeed, outbreaks of AHSV have been reported in
Morocco, the Middle East, and in Europe in the recent past [5–8].
For protective immunization of horses, attenuated virus vaccines
and inactivated AHSV vaccines have been used [9–11].
AHSV belongs to the genus Orbivirus of the family Reoviridae and
is structurally closely related to Bluetongue virus (BTV). The com-
plete virion particles have consecutive layers of proteins organized
into two capsids. The outer capsid has two proteins (VP2 and VP5)
and the inner capsid or ‘‘core” is composed of two major proteins,
VP7 and VP3, as well as the transcription complex of three proteins,
VP1, VP4 and VP6, and the viral genome of ten double-stranded RNA
(dsRNA) segments [12,13]. Because of this genomic feature, it haschemical Societies. Published by Ebeenverydifﬁcult todevelopa reversegenetics systemfor themem-
bers of the Reoviridae family. However, in recent years, reverse
genetics systems for several viruseswithin this family have been re-
ported [14–17]. Particularly, the reverse genetics system for
bluetongue virus (BTV), based on single-stranded RNA (ssRNA)
transfection, has been showntobehighlyefﬁcient. In anatural infec-
tion, following entry of the virus into the host cell, the viral core is
released into the cytoplasm where multiple ssRNA copies of viral
genome segments are produced. These ssRNAs act as messengers
for viral proteins and also templates for synthesis of dsRNA genome.
In this study, we demonstrate the recovery of infectious AHSV
from ssRNA synthesized from puriﬁed core particles (core tran-
scripts). We also show that it is possible to rescue reassortant
viruses by transfecting core transcripts from two different AHSV
serotypes. Moreover, we demonstrate that it is possible to intro-
duce transcript derived from plasmid DNA by T7 RNA polymerase
into the AHSV genome. Using this system, we have shown that the
replication of AHSV occurs in two stages, involving a primary rep-
lication cycle. This is consistent with previous observations on the
replication of BTV [18].2. Materials and methods
2.1. Cell lines and virus
BHK-21 cells (BSR clone) were maintained in Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM) (Sigma) supplemented with 4% (v/v)lsevier B.V. All rights reserved.
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serotype 6 (AHSV6) stocks were obtained by infecting BSR cells
at a multiplicity of infection (MOI) of 0.1 and harvesting 2–3 days
post-infection.
2.2. Puriﬁcation of African horse sickness virus cores
BSR cells were infected with AHSV4 or AHSV6 at an MOI of 0.05.
AHSV cores were puriﬁed using a modiﬁcation of the previous
methods [15,19]. Brieﬂy, BSR cells infected with AHSV were lysed
at 2 days post-infection in a chilled lysis buffer (100 mM Tris–
HCl, pH 8.8, 50 mM NaCl, 10 mM EDTA, 0.3% NP40). Nuclei and
insoluble cell debris were removed by centrifugation at 1400g
at 4 C for 15 min. The lysate was treated with 75 lg/ml of a-chy-
motrypsin at 35 C for 1 h and then with 0.2% (w/v) N-lauroyl sar-
cosyl at 25 C for 1 h. The samples were then centrifuged through a
discontinuous sucrose gradient of 70% and 40% (w/v) sucrose in
20 mM Tris–HCl (pH 8.8), 0.6 M MgCl2 at 141 000g at 16 C for
1.5 h. The interface was collected and diluted down to 30% (w/v)
sucrose. The diluted samples were centrifuged through a 40% (w/
v) sucrose cushion in 20 mM Tris–HCl (pH 8.0) buffer at
141 000g at 16 C for 1 h. The pellets were re-suspended in
20 mM Tris–HCl (pH 8.0).
Proteins from puriﬁed cores were analysed by denaturing 10%
polyacrylamide gel electrophoresis (SDS–PAGE) followed by stain-
ing with Coomassie blue R250.
2.3. Synthesis and puriﬁcation of AHSV ssRNA (core transcripts)
in vitro
Core transcripts were synthesized and puriﬁed using similar
method used for BTV as described previously [15] with some mod-
iﬁcations. Brieﬂy, 50 lg of AHSV cores were incubated at 30 C for
4 h in 500 ll of transcription reaction mix (100 mM Tris–HCl, pH
8.0, 4 mM rATP, 2 mM rGTP, 2 mM rCTP, 2 mM rUTP, 500 lM S-
adenosylmethionine, 6 mM dithiothreitol, 9 mM MgCl2, 50 lM
MnCl2) supplemented with 0.2 U/ll RNasin plus (Promega). Cores
were removed by centrifugation at 18 000g at 4 C for 45 min.
The supernatant was collected and incubated with 2 M LiCl at
4 C for 16 h to precipitate core transcripts. Core transcripts were
precipitated by centrifugation at 18 000g at 4 C for 15 min, re-
suspended into OPTI-MEM (Invitrogen) containing 0.1 U/ll RNasin
plus and puriﬁed using standard phenol/chloroform extraction
methods, which can completely remove the core particles. Puriﬁed
core transcripts were analysed by electrophoresis on a 0.8% aga-
rose gel in MOPS buffer in the presence of formaldehyde, using
standard techniques.
2.4. T7 plasmids for AHSV transcripts
T7 plasmids for AHSV transcripts used in the reverse genetics
system were synthesized as described previously [16] with some
modiﬁcations. Brieﬂy, dsRNA was extracted from puriﬁed core
particle and cDNA from each segment ampliﬁed using a se-
quence-independent method (FLAC). Each segment was cloned
and sequenced. For the purpose of this study, constructs of AHSV4
segment 4 (S4) and AHSV4 segment 5 (S5), encoding VP2 and NS1,
respectively, were prepared using the following primers:
A4M4T7_F (50-CTGGTCGACTAATACGACTCACTATAGTTAATTTAG
GATGGAACCTTACG-30) and A4M4 Eco105I_R (50-GACGTCGACTA
CGTAAGGTTATTAGGATTCCCCCTTG-30).
A4M5T7_F (50-CTGGTCGACTAATACGACTCACTATAGTTAAAGAA
CCTAGGCGGTTTGGC-30) and A4M5 BsmBI_R (50-CTGGTCGACCG
TCTCCGTAAGTTTGTGAACCAGGGGGATATG-30). Each functional
cassette has a T7 promoter and a restriction enzyme site to gener-
ate a correct 30 end.2.5. Synthesis of AHSV transcripts from cDNA plasmid clones
For synthesis of T7 transcripts corresponding to AHSV4 S4 and
S5 a similar protocol was used as described for BTV [16]. Capped
T7 transcripts were synthesized using mMESSAGE mMACHINE T7
Ultra Kit (Ambion) according to manufacturer’s procedures. The
synthesized RNA transcripts were re-suspended in nuclease-free
water and stored at 80 C until used.
2.6. Transfection of BSR cells with core transcripts and/or T7 transcript
Conﬂuent BSR monolayers were transfected once or twice with
AHSV core transcripts using Lipofectamine 2000 Reagent (Invitro-
gen) as describe previously [16,18,20]. For the recovery experi-
ment, various amounts of core transcripts were used for both
ﬁrst and second transfection. For the synthetic reassortment exper-
iment, 0.3 lg of T7 transcripts were mixed with 0.3 lg of core tran-
scripts and transfected to BSR cells at 18 h post ﬁrst-transfection
with 0.5 lg of core transcripts.
2.7. Extraction of dsRNA from recovered AHSV
Isolated plaques were picked up and used for infection of fresh
BSR monolayers. At 3 days post-infection, total RNA was extracted
from cells using Tri-reagent (Sigma) and dsRNA was puriﬁed using
standard method described previously [15]. Puriﬁed dsRNA was
analysed by nondenaturing 8% polyacrylamide gels (PAGE gel).
2.8. Reverse transcription-PCR (RT-PCR) ampliﬁcation of AHSV genome
segments
cDNA copies of AHSV genome segments were ampliﬁed from
viral dsRNA in a sequence-dependent manner using SuperScript
II (Invitrogen) as described in manufacture’s protocol. For ampliﬁ-
cation of S4 and S5, the same sets of primers for T7 plasmids were
used. For segment 7 (S7), segment 8 (S8) and segment 9 (S9), the
following primer sets were used: A4S7Fw (50-GTTAAAATTCGGT-
TAGGATGGACGC-30) and A4S7Rv (50-GTAAGTGTATTCGGTATTG-
CGTAT-30), A6S8Fw (50-GTTAAAAATCCGTTCGTCATCATGG-30) and
A6S8Rv (50-GTATGTTGAAATCCGCGGTTACATG-30) and A6S9Fw
(50-GTTAAATAAGTTGTCTCATGTCTTC-30) and A6S9Rv (50-GTAAGT-
TTTAAGTTGCCCTCAAGCT-30), respectively. The same sets of prim-
ers were used for subsequent PCR ampliﬁcation. All sets of primers
could amplify cDNA copies and PCR fragments of both AHSV4 and
AHSV6.
2.9. Electron microscopy
Aliquots of puriﬁed cores were absorbed onto Formvar/carbon
support ﬁlm copper 400 mesh grids (TAAB) for 1 min, washed with
water, and negatively stained with 2% (w/v) uranyl acetate. The
grids were examined under electron microscope.3. Results
3.1. Puriﬁcation of AHSV core particles and synthesis of in vitro
transcripts
For synthesis of core transcripts, AHSV4 and AHSV6 core parti-
cles were puriﬁed from BSR cells infected with either AHSV4 or
AHSV6 virus. Cells were harvested 2 or 3 days post-infection and
core particles were puriﬁed as described in Section 2.2. Puriﬁed
core particles were detected using electron microscopy (Fig. 1A)
and protein composition was veriﬁed by 10% SDS–PAGE gel (data
not shown). Both AHSV4 and AHSV6 core particles, with 60–
ig. 2. The recovery of AHSV from core transcripts. (A) BSR cells were ﬁrst
ansfected either 0.25 lg of AHSV4 core transcripts (left well) or 0.5 lg of AHSV6
re transcripts (right well), followed by the second transfection with the same
mount of each core transcripts and overlaid with media containing agarose. After
days, cells were ﬁxed and stained with 0.2% (w/v) crystal violet. (B) dsRNA
xtracted from isolated AHSV plaques. BSR cells were infected with individual
laques. At 3 days post-infection, dsRNA was extracted and analysed by PAGE.
arental AHSV4 (lane 1) and AHSV6 (lane 2), rescued viruses from AHSV4 (lanes 3–
) and AHSV6 (lanes 6–8), core transcripts and genome segments are indicated.
ote that S6 (VP5) migrates slower than S5 (NS1). Migration of these two segments
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particles.
Puriﬁed core particles were used for in vitro ssRNA synthesis as
described in Section 2.3. Synthesized core transcripts from both
serotypes were detected using denaturing agarose gels (Fig. 1B).
Approximately 10 lg of total core transcripts were synthesized
from 25 lg of AHSV4 core particles.
3.2. Recovery of AHSV from core transcripts
We have previously reported that a double-transfection of BTV
ssRNA is more efﬁcient than a single transfection for recovering
infectious particles, indicating that such enhanced virus recovery
is probably due to a primary replication cycle [18]. Thus, to in-
crease the chances to recover infectious AHSV from core tran-
scripts, BSR cells were transfected twice with either AHSV4 or
AHSV6 core transcripts. For AHSV4, 0.25 lg of core transcripts
were transfected to BSR cells followed by a second transfection
with the same amount at 18 h after the ﬁrst transfection. Clear, de-
ﬁned plaques were observed at 3 days post second-transfection
(Fig. 2A). Similarly, double-transfection of BSR cells with AHSV6
core transcripts generated plaques, although with less efﬁciency
than AHSV4 (Fig. 2A). These results demonstrate that infectious
virus can be rescued from RNA transcripts upon transfection into
cells. In contrast, no plaques were observed when core transcripts
were added to the BSR cells without any transfection reagent (data
not shown). To conﬁrm virus recovery in each case, three plaques
were picked up from each serotype and dsRNA were extracted
from them. The migration patterns of dsRNA segments extracted
from all six plaques were indistinguishable from those of the
parental AHSV serotypes (Fig. 2B). These results conﬁrmed that
both AHSV4 and AHSV6 were recovered from their corresponding
core transcripts.Fig. 1. AHSV cores and AHSV core transcripts. (A) Puriﬁed AHSV4 (left panel) and
AHSV6 (right panel) core particles stained with 2% uranyl acetate and observed by
electron microscopy. The bar represents 100 nm. (B) Proﬁle of AHSV core transcripts
analysed by denaturing 1% agarose gel. Lane 1, ssRNA markers (Promega); lane 2,
AHSV6 transcripts and lane 3, AHSV4 transcripts. The numbers on the left indicate
the lengths of the marker bands in nucleotides. The position of each segment is
indicated on the right.










is3.3. Efﬁciency of double-transfection
To investigate further if the efﬁciency of double-transfection is
due to increased amount of ssRNA, we examined effects of variable
amounts of ssRNAs for each transfection. The results obtained
clearly indicated that double-transfection either with 0.5 lg or
with 0.25 lg of core transcripts was more efﬁcient in the recovery
of AHSV4 than single-transfection with 1.0 lg of core transcripts
(Fig. 3, columns 1, 4 and 5). Moreover, even with as low as 50 ng
of transcripts in second transfection, virus recovery was signiﬁ-
cantly enhanced in comparison to the single-transfection with
large amount of transcripts (Fig. 3 columns 6–9). These results sug-
gested that the efﬁciency of double-transfection is not due to the
amount of RNA, but more likely due to primary replication which
is initiated by forming the primary replication complex composed
of the proteins provided by the ﬁrst transfection and viral genomic
RNA. The genome of the progeny virus is most likely from the tran-
scripts in the second transfection. To investigate this hypothesis,
we wanted to identify the source of the genome in the recovered
progeny virus. Therefore, BSR cells were ﬁrst transfected with
AHSV4 core transcripts, followed by second transfection with
AHSV6 core transcripts. To minimize the chances of recovering
virus from the ﬁrst set of transcripts, the amount of ssRNA not suf-
ﬁcient for rescuing infectious virus in a single-transfection was
determined (Fig. 3). A total of 48 plaques were picked and when
dsRNAs from each isolated plaque were analysed, it was clear that
all virus clones contain AHSV6 genome, the source of second trans-
fection transcripts. Results of three isolated plaques are presented
as an example (Fig. 4A, lanes 3–5). Note that the migration patterns
of S7, S8 and S9 are almost the same for the two serotypes. For
Fig. 3. The efﬁciency of double-transfection for virus recovery. BSR cells were
transfected with serial dilution of AHSV4 core transcripts once or twice, overlaid
with agarose and the number of plaques was counted at 3 days post-transfection.
Columns 1–3, numbers of plaques (means ± S.D.) recovered from single-transfec-
tion; columns 4–9, numbers of plaques (means ± S.D.) recovered from double-
transfection. The amounts of core transcripts are indicated at the bottom of each
column. Note that no virus was rescued from BSR cells transfected only once with
0.25 lg of transcripts.
Fig. 4. Second transfection provides the genomic RNAs. (A) dsRNA proﬁles of
plaques derived from BSR cells transfected ﬁrst with AHSV4 core transcripts
followed by AHSV6 core transcripts (lanes 3–5) or AHSV6 followed by AHSV4 core
transcripts (lanes 6–8) as described in the text. Parental AHSV4 (lane 1) and AHSV6
(lane 2) are included. (B) cDNA copies of S7, S8 and S9 were synthesized from
isolated viral dsRNA and ampliﬁed PCR products were digested with XhoI (upper
panel), BsaAI (middle panel) and StyI (lower panel), respectively. AHSV isolated
from BSR cells transfected either with AHSV6 followed by AHSV4 (lanes 4–6) or
with AHSV6 followed by AHSV4 transcripts (lanes 7–9), markers (lane 1) and
parental AHSV4 (lane 2) and AHSV6 (lane 3) are included. The numbers on the left
indicate the lengths of the markers in nucleotides.
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ciﬁc primers and the source of these genomic segments was deter-
mined by restriction enzymes digestion patterns (Fig. 4B, lanes 2–
6). Further, the serotypes of these segments were also conﬁrmed
by sequencing (data not shown). All three segments belonged to
AHSV6. Similarly, AHSV4 was recovered when BSR cells were
transfected ﬁrst with AHSV6 core transcripts and subsequently
with AHSV4 core transcripts (Fig. 4A, lanes 6–8 and Fig. 4B, lanes
7–9). These results showed that the source of genome in the prog-
eny virus were the transcripts from the second transfection and
strongly support the existence of a primary and secondary replica-
tion cycles.
3.4. Reassortment of genome segments by co-transfection with AHSV
core transcripts from two serotypes
The reassortment of segments naturally occurs during co-infec-
tion with different AHSV serotypes [21]. With the aim of develop-
ing a reverse genetics system for AHSV, the introduction of genome
segments from one AHSV serotype into another was investigated
as an intermediate step prior to the introduction of cDNA-derived
genome segments. First, we wanted to establish that reassortant
viruses can be generated solely by transfection of core transcripts
from two different serotypes. Thus BSR cells were ﬁrst transfected
only with AHSV4 core transcripts, followed by second transfection
with a mixture of AHSV4 and AHSV6 core transcripts. When the
genomic dsRNAs of isolated plaques were analysed by PAGE, al-
most all clones appeared to be reassortants between AHSV4 and
AHSV6 based on their dsRNA proﬁles in the gel as indicated by
three examples (Fig. 5, lanes 3–5). The serotypes of S7–S9 were
also determined using the same method as described in Section 3.3
(Fig. 5B, lanes 4–6). In Fig. 5, clone #1 contains S2, S6, S7 and S10 ofAHSV6 while the remaining six segments were from AHSV4. Sim-
ilarly, clone #2 contains S1, S3, S4 and S8 of AHSV4 and remaining
six segments were from AHSV6. For clone #3, only two segments,
S4 and S5, were from AHSV4 while the remaining eight segments
were from in AHSV6. These data demonstrate that co-transfection
with a mixture of viral transcripts is a viable strategy for the intro-
duction of genome segments from a different sources into an AHSV
genome.
3.5. The introduction of an AHSV4 segment derived from a cDNA clone
into the AHSV6 genome
The targeted replacement of a genome segment with a T7 tran-
script derived from a cDNA clone was subsequently investigated as
a model for the introduction of cloned sequences into the AHSV
genome. Based on a reassortment experiment with core transcripts
(Section 3.4), the introduction of the AHSV4 S4 (VP4) or S5 (NS1)
T7 transcripts (shown in Fig. 6A) into the genome of AHSV6 was
investigated. BSR cells were ﬁrst transfected with 0.5 lg of AHSV6
core transcripts followed by the second transfection with a mixture
of AHSV6 core transcripts (0.3 lg) and either T7 S4 (0.3 lg) or T7
S5 (0.3 lg) of AHSV4. The recovery of viruses containing AHSV4
Fig. 5. Reassortant progeny genome recovered from the co-transfection of BSR cells
with AHSV4 and AHSV6 core transcripts. (A) dsRNA proﬁles of plaques derived from
BSR cells transfected ﬁrst with AHSV4 then with a mixture of AHSV4 and AHSV6
core transcripts (lanes 3–5) as described in the text. Parental AHSV4 (lane 1) and
AHSV6 (lane 2) are included. Arrows indicate segments originating from AHSV4. (B)
cDNA copies of S7, S8 and S9 were synthesized from isolated viral dsRNA and
ampliﬁed PCR products were digested with XhoI (upper panel), BsaAI (middle panel)
and StyI (lower panel), respectively. Markers (lane1), parental AHSV4 (lane2) and
AHSV6 (lane 3), rescued reassortant viruses (lanes 4–6) are included. The numbers
on the left indicate the lengths of the markers in nucleotides.
Fig. 6. Reassortant progeny genome recovered from the co-transfection of BSR cells
with AHSV6 core transcripts and together with either S4 or S5 T7 transcripts of
AHSV4. (A) Denaturing 1% agarose gel of S4 and S5 T7 transcripts of AHSV4. Lane 1,
ssRNA markers; lane 2, AHSV4 core transcripts; lane 3, S5 T7 transcript and lane 4,
S4 T7 transcript. The numbers on the left indicate the lengths of the nucleotide
markers. (B) dsRNAs proﬁles of plaques recovered from BSR cells transfected ﬁrst
with AHSV6 core transcripts and then with a mixture of AHSV6 core transcripts and
either S4 (lanes 3–5) or S5 AHSV4 T7 transcript (lanes 6–8) as described in the text.
Parental AHSV4 (lane 1) and AHSV6 (lane 2) are included. Arrows indicate segments
originated from T7 transcripts. (C) cDNA copies of S4 and S5 were synthesized from
isolated viral dsRNA and ampliﬁed PCR products were digested with EcoRI (left
panel) and BglII (right panel), respectively. Reassortant viruses between AHSV6 core
transcripts and either S4 (lanes 4–6) or S5 (lanes 10–12) AHSV4 T7 transcripts,
markers (lanes 1 and 7) and parental AHSV4 (lanes 2 and 8) and AHSV6 (lanes 3 and
9) are included. The numbers on the left indicate the markers nucleotides.
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PAGE gel (Fig. 6B). The identity of S4 and S5 was further conﬁrmed
using RT-PCR, followed by digestion with restriction enzyme
(Fig. 6C) and sequencing (data not shown). The Majority of the res-
cued viruses were reassortants and consisted of AHSV4 S4 or S5 de-
rived from T7 transcripts (S4, 90% positive; S5, 70% positive).
These data demonstrated the recovery of the plasmid-derived
AHSV4 S4 and S5 into the genome of viable AHSV6.
4. Discussion
In the Reoviridae, core particles have a major role to transcribe
ssRNAs, which serve not only as mRNAs for synthesis of viral pro-
teins, but also as templates for synthesis of new dsRNA genome.
BTV core transcripts have already been reported to be infectious
when they are directly transfected into BSR cells [15]. In this study,
we demonstrate that a complete set of transcripts of AHSV, a clo-
sely related orbivirus, are also infectious. Moreover, we show some
evidence of the primary replication cycle using new approaches,which are different from those used in the BTV study [18]. Addi-
tionally, we succeeded in introducing plasmid-derived T7 tran-
scripts into the genome of viable AHSV.
In the BTV reverse genetics system, when the T7 derived tran-
scripts encoding six viral proteins (VP1, VP3, VP4, VP6, NS1 and
NS2) were used in the ﬁrst transfection and a complete set of 10
T7 transcripts were used in the second transfection, the virus
recovery was efﬁciently enhanced, suggesting that these six pro-
teins and viral genome made the primary replication complex
[18]. In this study we demonstrated that a double-transfection ap-
proach dramatically enhanced the AHSV recovery, even though a
total RNA amount used for transfection was considerably less than
in a single-transfection (Fig. 3). Moreover, double-transfection
experiments with two different serotypes revealed that the sero-
type speciﬁcity of the recovered virus always relied on the tran-
scripts used in the second transfection (Fig. 4). Surprisingly, no
reassortant virus could be recovered in this experiment, supporting
further the hypothesis that the transcripts of the second transfec-
tion are the source of the genome in the rescued viruses. Although
E. Matsuo et al. / FEBS Letters 584 (2010) 3386–3391 3391we need to investigate further on this phenomenon, these results
strongly suggest that ssRNAs from the ﬁrst transfection could
mainly provide the proteins to make the primary replication com-
plex with ssRNAs from second transfection as well as to maintain
the host cellular condition to accept ssRNAs from second transfec-
tion. In addition, these new usages of different serotypes’ core tran-
scripts could make it possible to investigate the early stage in virus
replication cycle of Reoviridae from different aspects.
The recovery of reassortant viruses by mixing core transcripts
from two different serotypes (Fig. 5) was an encouraging result
that led us to examine the possibility of introducing a plasmid
T7-derived segment into the AHSV genome. This approach is
important for investigating the effect of targeted mutations in viral
genome or insertion of tags into virus proteins. To this end, we ﬁrst
succeeded the introduction of the AHSV4 S4 or S5 T7 transcript
into the genome of AHSV6 with high efﬁciency of reassortment
(Fig. 6) indicating that other T7 derived AHSV transcripts could
similarly be incorporated.
In BTV, based on the results from core transcripts and the intro-
duction of single or double plasmid-derived segments into the gen-
ome, an entirely plasmid-derived reverse genetics system has been
developed [15,16]. Our success in the introduction of the plasmid-
derived ssRNA into the genome of viable AHSV could be the mile-
stone to develop a reverse genetics system for AHSV based entirely
on T7 derived transcripts.
Acknowledgements
We thank Maria McCrossan (LSHTM) for technical help with
electron microscopy. This work was funded by BBSRC (UK).
References
[1] Coetzer, J.A.W. and Guthrie, A.J. (2004) African Horse Sickness in: Infectious
Diseases of Livestock (Coetzer, J.A.W. and Tustin, R.C., Eds.), pp. 1231–1246,
Oxford University Press, Cape Town, Southern Africa.
[2] DuToit, R.M. (1944) The transmission of blue-tongue and horse-sickness by
Culicoides. Onderstepoort J. Vet. Sci. Anim. Ind. 19, 7–16.
[3] Purse, B.V., Mellor, P.S., Rogers, D.J., Samuel, A.R., Mertens, P.P. and Baylis, M.
(2005) Climate change and the recent emergence of bluetongue in Europe. Nat.
Rev. Microbiol. 3, 171–181.
[4] Gale, P., Brouwer, A., Ramnial, V., Kelly, L., Kosmider, R., Fooks, A.R. and Snary,
E.L. (2010) Assessing the impact of climate change on vector-borne viruses inthe EU through the elicitation of expert opinion. Epidemiol. Infect. 138, 214–
225.
[5] Wilson, A., Mellor, P.S., Szmaragd, C. and Mertens, P.P. (2009) Adaptive
strategies of African horse sickness virus to facilitate vector transmission. Vet.
Res. 40, 16.
[6] Maclachlan, N.J. and Guthrie, A.J. (2010) Re-emergence of bluetongue, African
horse sickness, and other Orbivirus diseases. Vet. Res. 41, 35.
[7] Zientara, S., Sailleau, C., Plateau, E., Moulay, S., Mertens, P.P. and Cruciere, C.
(1998) Molecular epidemiology of African horse sickness virus based on
analyses and comparisons of genome segments 7 and 10. Arch. Virol. Suppl.
14, 221–234.
[8] Sailleau, C., Hamblin, C., Paweska, J.T. and Zientara, S. (2000) Identiﬁcation and
differentiation of the nine African horse sickness virus serotypes by RT-PCR
ampliﬁcation of the serotype-speciﬁc genome segment 2. J. Gen. Virol. 81,
831–837.
[9] Alexander, R.A. (1934) The immunization of horses and mules against Horse
sickness by means of the neurotropic virus of mice and guinea-pigs. J. Vet. Sci.
Anim. Ind. 2, 375–391.
[10] von Teichman, B.F. and Smit, T.K. (2008) Evaluation of the pathogenicity of
African Horsesickness (AHS) isolates in vaccinated animals. Vaccine 26, 5014–
5021.
[11] Dubourget, P., Preaud, J.M., Detraz, N., Lacoste, F., Fabry, A.C., Erasmus, B.J. and
Lombard, M. (1992) Development, Production, and Quality Control of an
Industrial Inactivated Vaccine Against African Horse Sickness Virus Serotype 4
in: Bluetongue, African Horse Sickness and Related Orbiviruses: Proceedings
of the Second International Symposium (Walton, T.E. and Osburn, B.I., Eds.),
pp. 874–886, CRC Press, Boca Raton.
[12] Roy, P., Mertens, P.P. and Casal, I. (1994) African horse sickness virus structure.
Comp. Immunol. Microbiol. Infect. Dis. 17, 243–273.
[13] Grubman, M.J. and Lewis, S.A. (1992) Identiﬁcation and characterization of the
structural and nonstructural proteins of African horse sickness virus and
determination of the genome coding assignments. Virology 186, 444–451.
[14] Kobayashi, T. et al. (2007) A plasmid-based reverse genetics system for animal
double-stranded RNA viruses. Cell Host Microbe 1, 147–157.
[15] Boyce, M. and Roy, P. (2007) Recovery of infectious bluetongue virus from
RNA. J. Virol. 81, 2179–2186.
[16] Boyce, M., Celma, C.C. and Roy, P. (2008) Development of reverse genetics
systems for bluetongue virus: recovery of infectious virus from synthetic RNA
transcripts. J. Virol. 82, 8339–8348.
[17] Kobayashi, T., Ooms, L.S., Ikizler, M., Chappell, J.D. and Dermody, T.S. (2010) An
improved reverse genetics system for mammalian orthoreoviruses. Virology
398, 194–200.
[18] Matsuo, E. and Roy, P. (2009) Bluetongue virus VP6 acts early in the replication
cycle and can form the basis of chimeric virus formation. J. Virol. 83, 8842–8848.
[19] Mertens, P.P., Burroughs, J.N. and Anderson, J. (1987) Puriﬁcation and
properties of virus particles, infectious subviral particles, and cores of
bluetongue virus serotypes 1 and 4. Virology 157, 375–386.
[20] Celma, C.C. and Roy, P. (2009) A viral nonstructural protein regulates
bluetongue virus trafﬁcking and release. J. Virol. 83, 6806–6816.
[21] Potgieter, A.C., Page, N.A., Liebenberg, J., Wright, I.M., Landt, O. and van Dijk,
A.A. (2009) Improved strategies for sequence-independent ampliﬁcation and
sequencing of viral double-stranded RNA genomes. J. Gen. Virol. 90, 1423–
1432.
